AR and metastatic prostate carcinoma: Increases in oncogenic AR activity may be driven by somatic changes that upregulate crucial APUC genes in the metastatic prostate cancer tumors, such as HSD3B2 (1.8-fold increase) and SRD5A1 (2.1-fold increase).